Stanley E. Waintraub, MD

Articles by Stanley E. Waintraub, MD

Real-World Economic Value of a 21-Gene Assay in Early-Stage Breast Cancer

ByStanley E. Waintraub, MD,Donna McNamara, MD,Deena Mary Atieh Graham, MD,Andrew L. Pecora, MD,John Min, BS,Tommy Wu, BA,Hyun Gi Noh, MSC,Jacqueline Connors, RN, OCN,Ruth Pe Benito, MPH, BS,Kelly Choi, MD,Eric Schultz, BS,Stuart L. Goldberg, MD

December 20th 2017

Universal gene expression profiling of patients with stage II breast cancer resulted in outpatient savings of $11,000 (inclusive of testing costs) within 6 months of initiation of medical therapy.

Latest Updated Articles

Real-World Economic Value of a 21-Gene Assay in Early-Stage Breast Cancer
Published: December 20th 2017 | Updated:

Stanley E. Waintraub, MD

Articles by Stanley E. Waintraub, MD

Real-World Economic Value of a 21-Gene Assay in Early-Stage Breast Cancer

Latest Updated Articles

Trending on CGTlive®

FDA Picks Abeona’s XLRS Gene Therapy ABO-503 for RDEA Pilot Program

Krystal Biotech’s Neurotrophic Keratitis Gene Therapy Viral Vector Secures FDA Platform Technology Designation

Around the Helix: Cell and Gene Therapy Company Updates – October 15, 2025

BLA for Rocket’s LAD-I Gene Therapy Under Review by FDA Again

Tr1X's Multiple Sclerosis Cell Therapy TRX319 Cleared for US Trial